All In MedTech

Device Trial Radar · NCT05633004

Avicena LVDP Validation Study

Assessment of the Vivio System for the Non-Invasive Estimation of Left Ventricular Diastolic Pressure (LVDP) as an Aid in the Diagnosis of Heart Failure

Last checked: Nov 19, 2026Latest source record: Dec 1, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

406

Actual

Start

Sep 27, 2021

Primary completion

Sep 8, 2022

Study completion Sep 30, 2022

Sponsor

Lead sponsor
Ventric Health, LLCNot on our public-company list
Sponsor type
Industry
First posted
Dec 1, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated device
Yes
Who can join
All sexes, from 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to determine the relationship between non-invasive measurement of left ventricular diastolic pressure (LVDP) using the Vivio System, compared with invasively measured LVDP via direct measurement during left heart catheterization.

Conditions

  • Heart Failure

Interventions

  • VivioDevice

    Non-invasive estimation of Left-Ventricular End Diastolic Pressure (LVEDP)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary endpoints are the sensitivity and specificity of the Vivio Cuff System for predicting elevated versus non elevated LVEDP as compared to direct measurement of LVEDP in the combined Cath Lab and Healthy CohortsTime frame: 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Spectrum

    Grand Rapids, Michigan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.